Centocor sees growing demand for Remicade
Executive Summary
The Crohn's disease therapy Remicade (infliximab) posted $21.1 mil. in sales for the first quarter, compared to $23.9 mil. in the fourth quarter immediately following launch, Centocor said. "First quarter sales reflected the fact that pent-up demand for Remicade was largely satisfied in the fourth quarter," the firm said. "Demand for the drug is growing, reflecting the high level of physician and patient satisfaction we have seen since the drug became commercially available"